A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Study Summary

The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 \[PCWG2\]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).

Conditions

Prostatic Neoplasms

Interventions / Drugs

Apalutamide Placebo Androgen-deprivation Therapy (ADT)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment75 participants

Primary Completion—

Lead SponsorJanssen Research & Development, LLC

Data Retrieved2026-04-11 02:55:31.550229+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.